Lazara Garcia Cabezas
Family · Lehigh Acres, FLNPI 1003415092
Payments from drug & device makers
Across 323 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$997
- Lilly USA, LLC$559
- Bayer$553
- Esperion Therapeutics, Inc.$527
- GSK$480
- Amgen$413
- plus $3K from 23 others
What the payments were for
- Food & beverage$6,330100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $997 |
| Lilly USA, LLC | 31 | $559 |
| Bayer | 21 | $553 |
| Esperion Therapeutics, Inc. | 27 | $527 |
| GSK | 25 | $480 |
| Amgen | 30 | $413 |
| Pfizer | 20 | $388 |
| AbbVie | 13 | $280 |
| Boehringer Ingelheim | 9 | $250 |
| E.r. Squibb & Sons, L.L.C. | 11 | $225 |
| Novartis | 12 | $197 |
| Dexcom, Inc. | 6 | $196 |
| Boston Scientific | 5 | $187 |
| Sanofi-aventis U.S. LLC | 9 | $164 |
| Radius Health, Inc. | 7 | $134 |
| Xeris Pharmaceuticals, Inc. | 5 | $102 |
| Almatica Pharma LLC | 6 | $97 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $88 |
| Vanda Pharmaceuticals Inc. | 3 | $87 |
| Merck | 3 | $70 |
| Antares Pharma, Inc. | 3 | $57 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| AstraZeneca | 3 | $47 |
| Astellas Pharma US Inc | 2 | $46 |
| Abbott | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Exact Sciences | 1 | $24 |
| Convatec Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $13 |
How this compares
$6,330 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $89,795 |
| Famotidine | 83 | $1,385 |
| Atorvastatin Calcium | 138 | $1,274 |
| Ventolin HfaAlbuterol Sulfate | 11 | $976 |
| Methylprednisolone | 97 | $834 |
| Omeprazole | 36 | $757 |
| Rosuvastatin Calcium | 85 | $754 |
| Gabapentin | 44 | $732 |
| Diclofenac Sodium | 25 | $617 |
| Losartan Potassium | 48 | $540 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 27 | $533 |
| Triamcinolone Acetonide | 19 | $529 |
| Potassium Chloride | 17 | $520 |
| Glimepiride | 24 | $493 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 23 | $489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $997 | $89,79562 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Lehigh Acres
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.